Journals / Türk Hijyen ve Deneysel Biyoloji Dergisi / 2017 / Cilt: 74 - Sayı: 3

Enhancing sensitivity of chemoresistant ovarian cancer cells to TRAIL and FAS mediated apoptosis by radiation

Kemorezistant over kanser hücrelerinin TRAIL ve FAS aracılı apoptoz duyarlılıklarının radyasyon ile arttırılması

Pages
185–192
Publication Date
2022-11-05
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

Conclusion: This study has suggested that sublethal radiation treatment may simultaneously increase immunogenicity of tumor cells and the induction of antitumor immunity to chemoresistant ovarian cancer cells.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Objective: Death receptors initiate apoptotic signals following interaction with their cognate ligands.
📊
Key Findings & Data:Results: The majority of chemoresistant A2780- AD cells remain viable following a high dose ofcisplatin treatment, while the drug sensitive A2780 cells started to die following low dose drug exposure.
💡
Conclusion & Impact:Conclusion: This study has suggested that sublethal radiation treatment may simultaneously increase immunogenicity of tumor cells and the induction of antitumor immunity to chemoresistant ovarian cancer cells.
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Abstract

Objective: Death receptors initiate apoptotic signals following interaction with their cognate ligands. However, expressions of death receptors are often downregulated during ovarian cancer progression and it has been recently asserted that suppression of death receptors is associated with resistance to chemotherapeutic drugs in ovarian cancer cells. Radiotherapy is a common treatment modality for several cancer types and it has been reported that low-dose ionizing radiation modulates tumor microenvironment. The purpose of the present study is to determine if sublethal ionizing radiation will modulate the expression of common death receptors in chemoresistant ovarian cancer cells and to investigate if reversed expression of death receptors will enhance TRAIL or FAS ligand (FASL) mediated apoptosis. Methods: Flow cytometry analyses were performed to determine the effects of chemotherapeutic drug, cisplatin, on chemosensitive and chemoresistant ovarian cancer cells viability, cellular expressions of death receptors and TRAIL or FAS mediated apoptosis, following sub-lethal irradiation in drug resistant ovarian cancer cells. Results: The majority of chemoresistant A2780- AD cells remain viable following a high dose ofcisplatin treatment, while the drug sensitive A2780 cells started to die following low dose drug exposure. The results have demonstrated that 2 Gy or 5 Gy ionizing radiation enhances expression of death receptors, FAS and DR4, in multi drug resistant A2780-AD ovarian cancer cells. The data further have confirmed that sub-lethal ionizing radiation increases FAS/TRAIL-mediated apoptosis of the chemoresistant ovarian tumor cells. Conclusion: This study has suggested that sublethal radiation treatment may simultaneously increase immunogenicity of tumor cells and the induction of antitumor immunity to chemoresistant ovarian cancer cells.

Özet

Amaç: Ölüm reseptörleri, ligandları ile etkileşime girerek apoptotik sinyallerini başlatmaktadır. Ancak over kanserinin gelişimi sürecinde ölüm reseptörlerinin ekspresyonu sıklıkla baskılanmaktadır ve son yıllarda over baskılanmasının kemoterapötik ilaçlara karşı oluşturulan direnç mekanizmaları ile ilişkili olduğu öne sürülmüştür. Radyoterapi çeşitli kanser tiplerinde yaygın bir tedavi yöntemidir ve düşük dozda iyonize radyasyonun tümörün mikro çevresini etkilediği rapor edilmiştir. Bu çalışmanın amacı ölümcül olmayan iyonize radyasyonun kemorezistan over kanseri hücrelerinde ölüm reseptörlerinin ekspresyonunu değiştirip değiştirmeyeceğinin belirlenmesi ve expresyonu arttırılmış ölüm reseptörlerinin TRAIL ya da FAS ligand (FASL) aracılı apoptozu arttırıp arttırmayacağının araştırılmasıdır.başladıkları halde yüksek dozdaki sisplatin muamelesinin ardından kemorezistan A2780-AD hücrelerinin büyük bir kısmı canlılığını sürdürmüştür. Sonuçlar 2 Gy yada 5 Gy iyonize radyasyonun çoklu ilaçlara dirençli A2780-AD over kanseri hücrelerinde ölüm reseptörlerinin, FAS ve DR4, expresyonunu arttırdığını göstermiştir. Veriler ölümcül olmayan iyonize radyasyon, kemorezistan over kanseri hücrelerinin FAS ve TRAIL aracılı apoptozu arttırdığını doğrulamıştır. Sonuç: Bu çalışma düşük doz radyasyon tedavisinin doğal olarak tümör hücrelerinin immünojenitisini arttırabileceğini indükleyebileceğini akla getirmiştir.

🔖

Cite This Article

CACAN, E. (2022). Enhancing sensitivity of chemoresistant ovarian cancer cells to TRAIL and FAS mediated apoptosis by radiation. Türk Hijyen ve Deneysel Biyoloji Dergisi, Cilt: 74 - Sayı: 3, 185–192. https://ajindex.com/articles/625019

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (14)

  1. Smolle E, Taucher V, Haybaeck J. Malignant ascites in ovarian cancer and the role of targeted therapeutics. Anticancer research. 2014;34:1553- 61
  2. McEvoy LM, O’Toole SA, Spillane CD, Martin CM, Gallagher MF, Stordal B, et al. Identifying novel hypoxia-associated markers of chemoresistance in ovarian cancer. BMC cancer. 2015;15:547
  3. Muallem MZ, Braicu I, Nassir M, Richter R, Sehouli J, Arsenic R. ERCC1 expression as a predictor of resistance to platinum-based chemotherapy in primary ovarian cancer. Anticancer research. 2014;34:393-9
  4. Davis A, Tinker AV, Friedlander M. “Platinum resistant” ovarian cancer: what is it, who to treat and how to measure benefit? Gynecologic oncology. 2014;133:624-31
  5. Cacan E, Greer SF, Garnett-Benson C. Radiationinduced modulation of immunogenic genes in tumor cells is regulated by both histone deacetylases and DNA methyltransferases. International journal of oncology. 2015;47:2264-75
  6. Thorburn A. Death receptor-induced cell killing. Cellular signalling. 2004;16:139-44
  7. Cacan E, Spring AM, Kumari A, Greer SF, GarnettBenson C. Combination Treatment with Sublethal Ionizing Radiation and the Proteasome Inhibitor, Bortezomib, Enhances Death-Receptor Mediated Apoptosis and Anti-Tumor Immune Attack. International journal of molecular sciences. 2015;16:30405-21
  8. Wang S, El-Deiry WS. TRAIL and apoptosis induction by TNF-family death receptors. Oncogene. 2003;22:8628-33
  9. Kykalos S, Mathaiou S, Karayiannakis AJ, Patsouras D, Lambropoulou M, Simopoulos C. Tissue expression of the proteins fas and fas ligand in colorectal cancer and liver metastases. Journal of gastrointestinal cancer. 2012;43:224-8
  10. Yigit R, Massuger LF, Figdor CG, Torensma R. Ovarian cancer creates a suppressive microenvironment to escape immune elimination. Gynecologic oncology. 2010;117:366-72
  11. Zhu Q, Liu JY, Xu HW, Yang CM, Zhang AZ, Cui Y, et al. Mechanism of counterattack of colorectal cancer cell by Fas/Fas ligand system. World journal of gastroenterology: WJG. 2005;11:6125-9
  12. Cacan E. Histone Deacetylase-1-mediated Suppression of FAS in Chemoresistant Ovarian Cancer Cells. Anticancer research. 2016;36:2819- 26
  13. Yang F, Long W, Xuechuan H, Xueqin L, Hongyun M, Yonghui D. Upregulation of Fas in epithelial ovarian cancer reverses the development of resistance to cisplatin. BMB reports. 2015;48:30-5
  14. Schneiderman D, Kim JM, Senterman M, Tsang BK. Sustained suppression of Fas ligand expression in cisplatin-resistant human o